1. The diagnosis of and treatment recommendations for anxiety disorders;Allgulander, C., Hackett, D., Salinas, E., 2001. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br. J. Psychiatry 179, 15–22. Baldwin, D.S., Huusom, A.K., Maehlum, E., 2006. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br. J. Psychiatry 189, 264–272. Bandelow;Dtsch. Arztebl. Int.,2014
2. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development;de Bodinat;Nat. Rev. Drug Discov.,2010
3. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study;Dechartres;Ann. Intern. Med.,2011
4. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension;Fava;Can. J. Psychiatry,2006
5. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties;Guardiola-Lemaitre;Br. J. Pharmacol.,2014